The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Mineralocorticoid Blockade Reduces Vascular Injury in Stroke-Prone Hypertensive Rats
Open accessAbstract
Chronic treatment of saline-drinking stroke-prone spontaneously hypertensive rats (SHRSP) with agents that interfere with the formation or actions of angiotensin II (Ang II) prevents the development of stroke and renal vascular damage. Ang II, in addition to its direct vascular effects, stimulates the synthesis and release of aldosterone. To assess the role of aldosterone in the development of pathologic changes in these rats, we implanted time-release pellets containing 200 mg of the mineralocorticoid receptor antagonist, spironolactone, into 14 SHRSP at 7.5 weeks of age. Eight SHRSP littermates received placebo pellets. Over the period of study (3 to 4 weeks), systolic blood pressure (SBP) was not different between the groups. Spironolactone did not enhance water and electrolyte excretion. All placebo-treated SHRSP developed marked proteinuria (150±6 mg/d) whereas in spironolactone-treated SHRSP, urinary protein excretion (UPE) averaged 39±9 mg/d (P<.0001). In a second study to assess effects on survival, 6 SHRSP received spironolactone (10 mg/kg/d) and 6 received vehicle. All but one of the control rats displayed signs of stroke and died by 16 weeks of age, while the spironolactone-treated SHRSP remained asymptomatic through 19 weeks of age (P<.03). At 16 weeks of age, spironolactone-treated SHRSP were severely hypertensive (247±3 mm Hg), yet UPE remained at baseline levels. In contrast, preterminal UPE averaged 136±13 mg/d in control rats (P<.0001). In both studies, histopathologic examination revealed a marked protective effect of spironolactone against the development of malignant nephrosclerotic and cerebrovascular lesions. These observations indicate a vascular and end organ protective effect of spironolactone in the absence of lowered blood pressure in saline-drinking SHRSP and are consistent with a major role for mineralocorticoids as hormonal mediators of vascular injury.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Essential Hypertension: Renin and Aldosterone, Heart Attack and Stroke
Brunner, H. R., Laragh, J. H., Baer, L., Newton, M. A., Goodwin, F. T., Krakoff, L. R., Bard, R. H., & Bühler, F. R. (1972) · New England Journal of Medicine · doi:10.1056/nejm197203022860901 · Cited by 1,093
Establishment of the strokeprone spontaneously hypertensive rat (SHR)
Okamoto, K. (1972) · Circulation Research · Cited by 598
Role of aldosterone in the remnant kidney model in the rat.
Greene, E. L., Kren, S., & Hostetter, T. H. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118867 · Cited by 479
Three new epoxy-spirolactone derivatives: characterization in vivo and in vitro.
de Gasparo, M., Joss, U., Ramjoué, H. P., Whitebread, S. E., Haenni, H., Schenkel, L., Kraehenbuehl, C., Biollaz, M., Grob, J., & Schmidlin, J. (1987) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)22580-0 · Cited by 343
Regulation of Aldosterone Secretion
Quinn, S. J., & Williams, G. H. (1988) · Annual Review of Physiology · doi:10.1146/annurev.ph.50.030188.002205 · Cited by 313
Brilla, C. G., Matsubara, L. S., & Weber, K. T. (1993) · The American Journal of Cardiology · doi:10.1016/0002-9149(93)90239-9 · Cited by 278
Increased endothelial albumin permeability mediated by protein kinase C activation.
Lynch, J. J., Ferro, T. J., Blumenstock, F. A., Brockenauer, A. M., & Malik, A. B. (1990) · Journal of Clinical Investigation · doi:10.1172/jci114663 · Cited by 266
Regional Myocardial Blood Flow in Lambs with Concentric Right Ventricular Hypertrophy
ARCHIE, J. P., FIXLER, D. E., ULLYOT, D. J., BUCKBERG, G. D., & HOFFMAN, J. I. E. (1974) · Circulation Research · doi:10.1161/01.res.34.2.143 · Cited by 252
Determinants of cardiac fibrosis in experimental hypermineralocorticoid states
Young, M., Head, G., & Funder, J. (1995) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1995.269.4.e657 · Cited by 228
Malignant hypertension produced by treatment with desoxycorticosterone acetate and sodium chloride
(1943) · American Heart Journal · doi:10.1016/s0002-8703(43)90306-0 · Cited by 220
Cited by
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., & Wittes, J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909023411001 · Cited by 9,214
ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult
Hunt, S. A. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.08.022 · Cited by 4,154
2005 WRITING COMMITTEE MEMBERS, Hunt, S. A., Abraham, W. T., Chin, M. H., Feldman, A. M., Francis, G. S., Ganiats, T. G., Jessup, M., Konstam, M. A., Mancini, D. M., et al. (2009) · Circulation · doi:10.1161/circulationaha.109.192065 · Cited by 3,720
WRITING COMMITTEE MEMBERS, Hunt, S. A., Abraham, W. T., Chin, M. H., Feldman, A. M., Francis, G. S., Ganiats, T. G., Jessup, M., Konstam, M. A., Mancini, D. M., et al. (2005) · Circulation · doi:10.1161/circulationaha.105.167586 · Cited by 2,251
Hunt, S. A., Abraham, W. T., Chin, M. H., Feldman, A. M., Francis, G. S., Ganiats, T. G., Jessup, M., Konstam, M. A., Mancini, D. M., Michl, K., et al. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.11.013 · Cited by 1,374
Aldosterone in Congestive Heart Failure
Weber, K. T. (2001) · New England Journal of Medicine · doi:10.1056/nejmra000050 · Cited by 770
Aldosterone induces a vascular inflammatory phenotype in the rat heart
Rocha, R., Rudolph, A. E., Frierdich, G. E., Nachowiak, D. A., Kekec, B. K., Blomme, E. A. G., McMahon, E. G., & Delyani, J. A. (2002) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.01096.2001 · Cited by 655
Self-citationXiao, L., & Harrison, D. G. (2020) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2020.01.013 · Cited by 545
Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats
Blasi, E. R., Rocha, R., Rudolph, A. E., Blomme, E. A. G., Polly, M. L., & McMahon, E. G. (2003) · Kidney International · doi:10.1046/j.1523-1755.2003.00929.x · Cited by 542
Self-citationAldosterone: A Mediator of Myocardial Necrosis and Renal Arteriopathy
Rocha, R. (2000) · Endocrinology · doi:10.1210/en.141.10.3871 · Cited by 475
Self-citationSelective Aldosterone Blockade with Eplerenone Reduces Albuminuria in Patients with Type 2 Diabetes
Epstein, M., Williams, G. H., Weinberger, M., Lewin, A., Krause, S., Mukherjee, R., Patni, R., & Beckerman, B. (2006) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.00240106 · Cited by 459
Spironolactone Improves Angiotensin-Induced Vascular Changes and Oxidative Stress
Virdis, A., Neves, M. F., Amiri, F., Viel, E., Touyz, R. M., & Schiffrin, E. L. (2002) · Hypertension · doi:10.1161/01.hyp.0000034738.79310.06 · Cited by 399
The renin-angiotensin-aldosterone system and the kidney: effects on kidney disease
Brewster, U. C., & Perazella, M. A. (2004) · The American Journal of Medicine · doi:10.1016/j.amjmed.2003.09.034 · Cited by 390
Mehdi, U. F., Adams-Huet, B., Raskin, P., Vega, G. L., & Toto, R. D. (2009) · Journal of the American Society of Nephrology · doi:10.1681/asn.2009070737 · Cited by 388
Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension
Weinberger, M. H., Roniker, B., Krause, S. L., & Weiss, R. J. (2002) · American Journal of Hypertension · doi:10.1016/s0895-7061(02)02957-6 · Cited by 388
Bianchi, S., Bigazzi, R., & Campese, V. M. (2006) · Kidney International · doi:10.1038/sj.ki.5001854 · Cited by 338
Savoia, C., & Schiffrin, E. L. (2007) · Clinical Science · doi:10.1042/cs20060247 · Cited by 326
Aldosterone and end-organ damage
Brown, N. J. (2005) · Current Opinion in Nephrology and Hypertension · doi:10.1097/01.mnh.0000165889.60254.98 · Cited by 320
Nishiyama, A., Yao, L., Nagai, Y., Miyata, K., Yoshizumi, M., Kagami, S., Kondo, S., Kiyomoto, H., Shokoji, T., Kimura, S., et al. (2004) · Hypertension · doi:10.1161/01.hyp.0000118519.66430.22 · Cited by 314
Role of Aldosterone in Renal Vascular Injury in Stroke-Prone Hypertensive Rats
Rocha, R., Chander, P. N., Zuckerman, A., & Stier, C. T. (1999) · Hypertension · doi:10.1161/01.hyp.33.1.232 · Cited by 310
Self-citationRocha, R., Martin-Berger, C. L., Yang, P., Scherrer, R., Delyani, J., & McMahon, E. (2002) · Endocrinology · doi:10.1210/en.2002-220120 · Cited by 308
Self-citationRickard, A. J., Morgan, J., Tesch, G., Funder, J. W., Fuller, P. J., & Young, M. J. (2009) · Hypertension · doi:10.1161/hypertensionaha.109.131110 · Cited by 303
Rossing, K., Schjoedt, K. J., Smidt, U. M., Boomsma, F., & Parving, H.-H. (2005) · Diabetes Care · doi:10.2337/diacare.28.9.2106 · Cited by 299
Edwards, N. C., Steeds, R. P., Stewart, P. M., Ferro, C. J., & Townend, J. N. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.03.066 · Cited by 286
Aldosterone in the development and progression of renal injury
Hollenberg, N. K. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.00701.x · Cited by 273
The Pathophysiology of Aldosterone in the Cardiovascular System
ROCHA, R., & FUNDER, J. W. (2002) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2002.tb04415.x · Cited by 261
Self-citationBorn-Frontsberg, E., Reincke, M., Rump, L. C., Hahner, S., Diederich, S., Lorenz, R., Allolio, B., Seufert, J., Schirpenbach, C., Beuschlein, F., et al. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-2116 · Cited by 261
Navaneethan, S. D., Nigwekar, S. U., Sehgal, A. R., & Strippoli, G. F. M. (2009) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.04750908 · Cited by 258
Review of aldosterone- and angiotensin II-induced target organ damage and prevention
Struthers, A. (2004) · Cardiovascular Research · doi:10.1016/j.cardiores.2003.11.037 · Cited by 257
Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo
Brown, N. J., Nakamura, S., Ma, L., Nakamura, I., Donnert, E., Freeman, M., Vaughan, D. E., & Fogo, A. B. (2000) · Kidney International · doi:10.1046/j.1523-1755.2000.00277.x · Cited by 255
Endothelin Antagonism on Aldosterone-Induced Oxidative Stress and Vascular Remodeling
Pu, Q., Neves, M. F., Virdis, A., Touyz, R. M., & Schiffrin, E. L. (2003) · Hypertension · doi:10.1161/01.hyp.0000078357.92682.ec · Cited by 255
Aldosterone Potentiates Angiotensin II–Induced Signaling in Vascular Smooth Muscle Cells
Mazak, I., Fiebeler, A., Muller, D. N., Park, J.-K., Shagdarsuren, E., Lindschau, C., Dechend, R., Viedt, C., Pilz, B., Haller, H., et al. (2004) · Circulation · doi:10.1161/01.cir.0000131860.80444.ab · Cited by 218
Management of Glomerular Proteinuria: A Commentary
Wilmer, W. A., Rovin, B. H., Hebert, C. J., Rao, S. V., Kumor, K., & Hebert, L. A. (2003) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000100145.27188.33 · Cited by 217
Connell, J. M. C., MacKenzie, S. M., Freel, E. M., Fraser, R., & Davies, E. (2008) · Endocrine Reviews · doi:10.1210/er.2007-0030 · Cited by 182
Chung, E. Y., Ruospo, M., Natale, P., Bolignano, D., Navaneethan, S. D., Palmer, S. C., & Strippoli, G. F. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007004.pub4 · Cited by 157
White, W. B., Hanes, V., Chauhan, V., & Pitt, B. (2006) · Hypertension · doi:10.1161/01.hyp.0000232179.60442.84 · Cited by 119
Metadata
- Authors
- Rocha, R., Chander, P. N., Khanna, K., Zuckerman, A., & Stier, C. T.
- Venue
- Hypertension
- Published
- 1998-01
- Volume
- 31
- Issue
- 1
- Pages
- 451-458
- ISSN
- 0194-911X (ISSN-L)
- 1524-4563
- OpenAlex
- W2148155169
- Cited by
- 496
- References
- 31
- FWCI
- 12.56
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.